| Background: Genetic polymorphisms in the endoplasmic reticulum aminopeptidase
gene ERAP2 has been attributed with the etiopathogenesis of ankylosing spondylitis
(AS). Here we assessed the association of ERAP2 gene single nucleotide polymorphisms
(SNPs) with AS predisposition in Iranian patients and determined their effect
on the inflammatory state of the patients.
Methods: For genotyping of rs2548538, rs2287988, and rs17408150 SNPs using a
real-time
allelic discrimination approach, DNA was extracted from the whole blood
of 250 AS patients and 250 healthy individuals. RNA of the peripheral blood mononuclear
cells was separated, cDNA was synthesized, and transcriptional levels of cytokines,
including interleukin (IL)-17A,
IL-23,
IL-10,
and transforming growth factor-β,
were measured. Enzyme-linked
immunosorbent assay was used to measure the
serum concentration on the cytokines.
568 | EBRAZEH et al.
1 | INTRODUC TION
Ankylosing spondylitis (AS) is a chronic autoimmune disease and is
characterized by involvement of spine and sacroiliac joints, which
causes spinal deformities, increased disability, and mortality.1 A bulk
of research has suggested a significant role for genetic variations in
the etiology and pathogenesis of AS,2,3 in spite of the remarkable
involvement of environmental factors as well as aberrant epigenetic
regulations.4-8
The pathogenesis of AS is complicated, and earlier
research concentrated on the misfolding of the human leukocyte antigen
(HLA)-B27
molecule in disease susceptibility; however, genetic
studies have proposed that HLA-B27
accounts for a small part of the
overall AS risk.9 Epidemiological investigations has shown that the
HLA-B27
gene is carried by almost 90% of AS patients, whereas only
1%-5%
of individuals carrying the HLA-B27
gene will be affected
with AS in the future.10 These observations imply the involvement
of non-HLA
genes in AS risk.
Endoplasmic reticulum aminopeptidase (ERAP) 2 is an enzyme that
belongs to the zinc-containing
metallopeptidase family and the corresponding
gene is located on the chromosome 5q15. This enzyme is
found within the endoplasmic reticulum, which is involved in priming
peptides during the antigen presentation pathway via the major histocompatibility
complex class I.11 In comparison to ERAP1, data are
lacking about the attribution of ERAP2 polymorphisms with AS predisposition.
4,12,13 A number of genetic polymorphisms in the ERAP2 gene
have been attributed to produce alterations in the protein structure and
function. The AS-protective
ERAP2 gene single nucleotide polymorphism
(SNP) rs224837414 alters the splicing site in the exon 10, leading
to synthesis of a lengthy exon 10 transcript.15 As a loss of enzyme
polymorphism, rs2248374 causes no protein expression of ERAP2 and
has been attributed with downregulation of major histocompatibility
complex class I molecule levels on the cell surface.15 Another variant is
rs2549782 SNP, which confers a modulation in the specificity as well as
functional velocity of the enzymatic activity of ERAP2.14,16 ERAP2 gene
rs2549782 SNP shows a linkage disequilibrium (LD) with other ERAP2
SNPs, including rs2548538, rs2287988, rs1056893, and rs2248374,
which are marker SNPs that constitute A and B haplotypes that are associated
with protein expression of ERAP2.15 In addition, ERAP2 gene
rs17408150 leads to substitution of a T with an A at codon 669 (p.Leu-
669Gln), which alters the leucine residue to glutamine, producing a significant
effect on the ERAP2 enzyme function.17
Association of ERAP1 SNPs with AS susceptibility in Iranian
patients has already been reported in our previous studies.18-21
Furthermore, we recently indicated the association of ERAP2 gene
SNPs with AS susceptibility in HLA-B27-
positive
individuals.22 With
respect to the involvement of genetic variations in the alteration
of ERAP2, it seems that evaluation of such SNPs is worthwhile.
Hence, this study aims to determine the associations of ERAP2 gene
rs2548538, rs2287988, and rs17408150 SNPs, for the first time to
the best of our knowledge, in an Iranian AS population. Furthermore,
the possible role of these SNPs was investigated in the control of
inflammatory and immunomodulatory mediators in AS.
2 | MATERIAL S A ND M E THODS
2.1 | Study participants
In this investigation, 250 individuals with AS and 250 persons as
healthy controls were included (Table 1). The 1984 modified New
York Criteria were used to diagnose AS.23 Healthy controls had no
background diseases or history of AS or other autoimmune diseases,
neither in them nor in family members, and were matched for age
and gender with the case group. AS patients were selected from
individuals who were recruited to Shahid Rajaee and Emam Reza
Hospitals affiliated with Alborz and Tabriz University of Medical
Sciences, Iran and outpatient Rheumatology Clinics of the Tabriz
University of Medical Sciences during 2015 to 2020. Approval of
Results: Three ERAP2 gene SNPs were not associated significantly with AS risk.
Nonetheless, rs2287988 and rs17408150 SNPs showed statistically significant association
with susceptibility to the disease in those AS patients who were positive for
human leukocyte antigen (HLA)-B27.
Transcriptional level and serum concentration
of IL-17A
and IL-23
were higher, but those of IL-10
were lower in both AS patients
and the HLA-B27-
positive
patient group relative to the control group. Nevertheless,
ERAP2 gene SNPs in the HLA-B27-
positive
AS patients did not affect the transcription
level and serum concentration of cytokines.
Conclusions: ERAP2 gene rs2287988 and rs17408150 SNPs are associated with susceptibility
to AS, but they are probably not determining the levels of IL-17A,
IL-23,
and
IL-10
in this disease. |